J Cerebrovasc Endovasc Neurosurg > Volume 17(3); 2015 > Article
Hwang, Hwang, Kwon, Kim, Ban, Han, Bae, Kim, Bang, Oh, Lee, and Jeong: Endovascular Treatment for Acute Ischemic Stroke Patients over 80 Years of Age



We evaluated the effect of endovascular treatment (EVT) for acute ischemic stroke in patients over 80 years of age.

Materials and Methods

The records of 156 acute stroke patients aged over 80 years who were considered as candidates for EVT were analyzed. Fifty-six patients (35.9%, EVT group) underwent EVT and 100 patients (64.1%, non-EVT group) did not. Outcomes, in terms of functional outcomes and rates of symptomatic hemorrhage, in-hospital morbidity and mortality, were compared between groups. Each comparison was adjusted for age, time from onset, initial National Institute of Health Stroke Scale, and pre-stroke modified Rankin Scale (mRS).


More patients in the EVT group achieved good outcomes (mRS score of 0-2) at 3 months (35.7% vs. 11.0%, adjusted odds ratio [OR] 4.779 [95% confidence interval 1.972-11.579], p = 0.001) and 12 months (35.7% vs. 14.0%, adjusted OR 3.705 [1.574-8.722], p = 0.003) after stroke. During admission, rates of hospital-acquired infection including pneumonia (12.5% vs. 29.0%, adjusted OR 0.262 [0.098-0.703], p = 0.008) and urinary tract infection (16.0% vs. 34.0%, adjusted OR 0.256 [0.099-0.657], p = 0.005) were significantly lower in the EVT group. More symptomatic hemorrhages (10.7% vs. 2.0%, adjusted OR 6.859 [1.139-41.317], p = 0.036) occurred in the EVT group, but no significant difference was observed in in-hospital mortality rate (12.5% vs. 8.0%, adjusted OR 1.380 [0.408-4.664], p = 0.604).


EVT improved functional outcome and reduced the risk of hospital-acquired infections in acute stroke patients over 80 years of age without increasing the risk of in-hospital mortality, although symptomatic hemorrhage occurred more frequently after EVT.


Age is an important risk factor for stroke occurrence. Approximately 30% of acute strokes occur in those older than 80 years of age.6)9)24) However, elderly patients tend to have high rates of poor outcomes and in-hospital mortality.1)4)8)13)14)16)17)23)25)26)30) Furthermore, family members of elderly patients are often reluctant to accept aggressive treatment. Recently, prospective trials have shown the benefit of endovascular treatment (EVT) for acute ischemic stroke.5)12)20)22)32) However, some trials included only patients aged 80 or less,20)32) and although trial inclusion criteria had no age limitation, a small proportion of elderly patients over 80 years were included.5)12)22) Therefore, the evidence supporting that endovascular treatment can be actively recommended for elderly patients as for younger patients is not sufficient.
To determine whether EVT for acute ischemic stroke is also beneficial in acute ischemic stroke patients over 80 years of age who are candidates for EVT, outcomes were compared between patients who underwent EVT and those who did not, in terms of functional outcomes and rates of symptomatic hemorrhage, in-hospital morbidities, and mortality.


Patient Selection

This retrospective study was approved by our Institutional Review Board. From a stroke registry (January 2009-March 2014) at our institution, data was collected on patients matching the EVT criteria for acute ischemic stroke of our institution: (1) time from onset < 8 hours, (2) major artery occlusion (internal carotid artery, middle cerebral artery [M1 and M2], basilar artery, or vertebral artery), (3) diffusion-perfusion mismatch on MRI (> 120% difference between diffusion weighted imaging and time to peak map), (4) an initial National Institute of Health Stroke Scale [NIHSS] score of ≥ 5, and (5) within time from onset of 4.5 hours, no clinical response to intravenous tPA, as described in previous studies.21)28) Patients who had intracranial hemorrhage, large infarctions (infarction size on diffusion MRI ≥ 1/3 on middle cerebral artery territory), bleeding diathesis, or serious illnesses affecting life expectancy including malignancy were excluded.
For 478 patients matching the EVT criteria retrieved from the registry, additional criteria were applied: age > 80 years and a prestroke modified Rankin Scale (mRS) score of ≤ 2. A total of 156 patients were selected as study subjects. To ensure agreement with the above mentioned criteria, the clinical and radiologic data of the patients were re-reviewed by two investigators (K.H. and C.H.K.). The stroke MRI protocol and the method of measuring diffusion-perfusion mismatch used have been previously described.18)

Patient management

At our institution, intravenous (IV) administration of tissue plasminogen activator (tPA) is considered, regardless of patient age, when indicated. Accordingly, of the 156 study subjects, tPA was administered in 95 patients matching IV tPA indication, but none of them showed a clinical response. In the remaining 61 patients, IV tPA was not used, from passing its time window in 58 patients or from a previous history of intracranial hemorrhage in 3 patients.
Unlike IV tPA administration, EVT for patients over 80 years of age was not actively recommended during the study period. Information on risks and benefits of EVT was provided to first-degree family members (spouse, sons, and daughters) and EVT was performed when they agreed. Because none of the patients were clearly conscious, they were unable to participate in this decision. Of the 156 study subjects, family members of 100 (64.1%, non-EVT group) patients refused EVT, thus they received standard medical treatment in the stroke unit in accordance with stroke guidelines.19) The remaining 56 (35.9%, EVT group) patients underwent EVT according to agreement of family members. In line with our EVT protocol, we primarily used clot retrieval using a Penumbra reperfusion catheter (Penumbra, Alameda, California) or a Solitaire FR stent (ev3, Plymouth, Minnesota). Intra-arterial infusion of fibrinolytics was reserved for cases with a remaining small amount of thrombi or distal migrating emboli. Technical details have been previously described.3)21)28) After EVT, they were also managed according to the standard treatment guidelines in the stroke unit.

Data collection

Basic demographic and clinical data (past history, occlusion site, Trial of Org 10172 Acute Stroke Treatment [TOAST] classification, time from onset, initial NIHSS score, IV tPA use, hemorrhage, in-hospital mortality, and mRS score [prestroke, and at 3 and 12 months after stroke]) were retrieved from the stroke registry. According to the criteria proposed by the European Cooperative Acute Stroke Study (ECASS) group,15) hemorrhage was classified as: hemorrhagic infarction type 1 (HI-1), hemorrhagic infarction type 2 (HI-2), parenchymal hematoma type 1 (PH-1), or parenchymal hematoma type 2 (PH-2). Symptomatic hemorrhage was defined as one associated with a ≥ 4-point increase in NIHSS score or a 1-point deterioration in level of consciousness.11) The stroke registry was controlled by two stroke neurologists (H.J.B. and M.K.H.). Discrepancies were resolved by consensus during weekly registry meetings.
In-hospital morbidities, including the need for endotracheal intubation, gastrointestinal bleeding, pneumonia, and urinary tract infection (UTI), were obtained by review of medical records (S.P.B. and B.L.). Gastrointestinal bleeding included hematemesis and melena. Patients were considered to have a hospital-acquired infection, when they had clinical, radiological, and laboratory findings compatible with infection and the organism was confirmed by culture.
The angiographic outcomes of patients who underwent EVT were reviewed and graded by two neurointerventionists (G.H. and O.K.K) using Thrombolysis in Cerebral Ischemia (TICI) grades. Successful recanalization was defined as a TICI grade of ≥ 2b. All complications that occurred during EVT were documented.

Measurement of the Effects of EVT

The effects of EVT were determined using: (1) good functional outcome (defined as a mRS score of 0-2) rates at 3 and 12 months after stroke, (2) symptomatic hemorrhage rates, (3) in-hospital morbidity rates (endotracheal intubation, gastrointestinal bleeding, pneumonia, and UTI), and (4) in-hospital mortality rates.

Statistical analyses

Statistical analysis was performed using STATA (version 13, STATA Corp LP, College Station, TX). The Mann-Whitney U test was used for bivariate analysis of continuous variables and the χ2 or Fisher's exact test for bivariate analysis of nominal factors. The effects of EVT were compared using binary logistic regression analysis, adjusted for confounders significantly associated with outcome after ischemic stroke: age (< 85 or ≥ 85 years), time from onset (< 4.5 or 4.5-8 hours), initial NIHSS score (moderate, 5-14 or severe, ≥ 15), and prestroke mRS score (0 or 1-2). "tPA use" was excluded from the logistic regression models, because of a lack of clinical response after tPA use in all cases and correlation with time from onset causing a multicollinearity problem. Two-sided probability values of < 0.05 were considered to indicate statistical significance.


Basic demographic and clinical data were not significantly different in the EVT and non-EVT groups (Table 1). In the EVT group, successful recanalization (TICI grade ≥ 2b) was achieved in 46 patients (82.1%). Of these, 25 patients did not achieve good outcomes and thus, futile recanalization, defined as mRS ≥ 3 despite successful recanalization, was 54.3%. Complications occurred in 3 (5.4%) patients during EVT: vessel rupture in 2 patients and intracranial artery dissection in 1 patient. Of these, good outcomes were achieved in 2 patients at 3 and 12 months after stroke. Recanalization failed in 1 patient with vessel rupture, whose outcome was poor (mRS 5 at 3 and 12 months), although bleeding was stopped by temporary balloon occlusion.
At 3 months after stroke, good functional outcomes were achieved in a greater portion of patients in the EVT group than in the non-EVT group (20 [35.7%] vs. 11 [11.0%], adjusted odds ratio [OR] 4.779, 95% confidence interval [CI] 1.972-11.579, p = 0.001; Table 2 and Fig. 1A). At 12 months follow-up, this trend continued and the good functional outcome rate was significantly higher in the EVT group than in the non-EVT groups (20 [35.7%] versus 14 [14.0%], adjusted OR 3.705, 95% CI 1.574-8.722, p = 0.003; Fig. 1B). In the non-EVT group, proportions of patients who were severely disabled or dead (mRS score of 4-6) were over 80% and significantly higher than in the EVT group at 3 months (83 [83.0%] vs. 28 [50.0%], adjusted OR 6.950, 95% CI 2.844-16.985, p < 0.001) and 12 months (82 [82%] vs. 32 [57.1%], adjusted OR 4.180, 95% CI 1.837-9.510, p = 0.001) after stroke (Fig. 1A, B).
Of in-hospital morbidities, pneumonia (7 [12.5%] versus 29 [29.0%], adjusted OR 0.262, 95% CI 0.098-0.703, p = 0.008) and UTI (9 [16.1%] versus 34 [34.0%], adjusted OR 0.256, 95% CI 0.099-0.657, p = 0.005) were significantly less frequent in the EVT group during admission (Table 2).
Hemorrhage occurred in 40 (25.6%) patients, including 8 (5.1%) with symptomatic hemorrhage during admission. Although hemorrhage types (HI, 6 [10.7%] vs. 11 [11.0%]; PH, 9 [16.1%] vs. 14 [14.0%], p = 0.941) were similar in the two groups, symptomatic hemorrhage rates were significantly higher in the EVT group (6 [10.7%] vs. 2 [2.0%], adjusted OR 6.859, 95% CI 1.139-41.317, p = 0.036).
In-hospital mortality rate did not differ significantly between the EVT and non-EVT groups (7 [12.5%] vs. 8 [8.0%], adjusted OR 1.380, 95% CI 0.408-4.664, p = 0.604).


The present study shows that EVT for acute ischemic stroke was associated with good functional outcomes at 3 and 12 months after stroke in patients over 80 years of age who were candidates for EVT. It also reduced rates of in-hospital morbidities, such as hospital-acquired infections. Although symptomatic hemorrhage occurred more frequently after EVT, overall functional outcome of elderly patients treated by EVT was still better and in-hospital mortality rate was not higher than that of patients not treated with EVT.
Our results indicate that the benefit of EVT for acute ischemic stroke is maintained even in patients over 80 years of age. Therefore, elderly patients should not be simply excluded from EVT candidates because of their age. This is consistent with subgroup analysis of recent prospective trials reporting that no significant interaction was detected between the benefit of EVT and age.5)12)
In addition to functional outcomes, in-hospital morbidities were also evaluated as a primary outcome of EVT, because these often lead to unfavorable or fatal outcome in elderly patients.8)13) We found that pneumonia and UTI developed more frequently in the non-EVT group. Poor clinical condition in patients with acute ischemic stroke is associated with these in-hospital morbidities and, in turn, their developments are predictors for unfavorable outcome and mortality.2)7)10)27)29)31)33)34)35)36) Therefore, these findings suggest that a better clinical condition achieved by EVT would reduce in-hospital morbidities, contributing to a more favorable outcome in EVT groups.
Symptomatic hemorrhage is an important complication associated with thrombolysis for acute ischemic stroke. Especially in elderly patients with acute ischemic stroke, symptomatic hemorrhage is frequent and associated with high rates of in-hospital mortality and poor outcome.1)4)8)13)14)16)17)23)25)26)30) In the current study, however, in-hospital mortality rates were not different between the two study groups. In addition, more than 80% of patients not treated by EVT were severely disabled or dead (mRS score of 4-6) due to acute stroke or its sequelae at 3 and 12 months after stroke, thus this proportion was found to be much higher than that of the EVT group. Therefore, these results indicate that the benefit of EVT overweighs the risk of symptomatic hemorrhage after EVT.
In practice, we frequently encounter elderly patients with acute ischemic stroke, but no consensus has been reached on this issue. Although our results do not provide definite evidence obtained from a well-designed randomized study, we believe that they could provide some useful information for physicians and patients, until sufficient data become available.
Several limitations of the current study should be addressed. These include its retrospective nature, single center experience, and its relatively small cohort. In addition, selection bias is likely to have been introduced by involving family members in the treatment decision-making process, and the general management afforded to both EVT and non-EVT groups may have been less than aggressive due to considerations of patient age. Nevertheless, the general management guidelines followed were identical for the EVT and non-EVT groups and all patients were managed without abandoning treatment, because only patients whose family-members agree on treatment for stroke are permitted to be referred to our tertiary referral hospital.


The present study demonstrated that EVT improved functional outcomes at 3 and 12 months after stroke in patients over 80 years of age with acute ischemic stroke who were candidates for EVT. It also reduced rates of hospital-acquired infections. These results indicate that the benefit of EVT for acute ischemic stroke is maintained in elderly patients. In these patients, symptomatic hemorrhage occurred more frequently after EVT, but the benefit of EVT overweighs the risk of symptomatic hemorrhage, considering the high rate of poor outcomes in patients who did not undergo EVT. Accordingly, our findings suggest that EVT can be considered in elderly patients, if indicated.


Disclosure: The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.


1. Alshekhlee A, Mohammadi A, Mehta S, Edgell RC, Vora N, Feen E, et al. Is thrombolysis safe in the elderly?: analysis of a national database. Stroke. 2010 10;41(10):2259-2264;
crossref pmid
2. Aslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR. GAIN International Steering Committee and Investigators. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol. 2004 1;11(1):49-53;
crossref pmid
3. Bang JS, Oh CW, Jung C, Park SQ, Hwang KJ, Kang HS, et al. Intracranial stent placement for recanalization of acute cerebrovascular occlusion in 32 patients. AJNR Am J Neuroradiol. 2010 8;31(7):1222-1225;
crossref pmid pmc
4. Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke. 2006 2;37(2):440-446;
crossref pmid
5. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 1;372(1):11-20;
crossref pmid
6. Bonita R, Anderson CS, Broad JB, Jamrozik KD, Stewart-Wynne EG, Anderson NE. Stroke incidence and case fatality in Australasia. A comparison of the Auckland and Perth population-based stroke registers. Stroke. 1994 3;25(3):552-557;
crossref pmid
7. Davenport RJ, Dennis MS, Warlow CP. Gastrointestinal hemorrhage after acute stroke. Stroke. 1996 3;27(3):421-424;
crossref pmid
8. Derex L, Nighoghossian N. Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients. Nat Rev Neurol. 2009 9;5(9):506-511;
crossref pmid pdf
9. Di Carlo A, Baldereschi M, Gandolfo C, Candelise L, Ghetti A, Maggi S, et al. Stroke in an elderly population: incidence and impact on survival and daily function. The Italian Longitudinal Study on Aging. Cerebrovasc Dis. 2003 2;16(2):141-150;
crossref pmid
10. Finlayson O, Kapral M, Hall R, Asllani E, Selchen D, Saposnik G. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. Neurology. 2011 10;77(14):1338-1345;
crossref pmid
11. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999 12;282(21):2003-2011;
crossref pmid
12. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med. 2015 3;372(11):1019-1030;
crossref pmid
13. Group TNt-PSS. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997 11;28(11):2119-2125;
crossref pmid
14. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 3;363(9411):768-774;
crossref pmid
15. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995 10;274(13):1017-1025;
crossref pmid
16. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA. 2004 10;292(15):1831-1838;
crossref pmid
17. Hussein HM, Georgiadis AL, Vazquez G, Miley JT, Memon MZ, Mohammad YM, et al. Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. AJNR Am J Neuroradiol. 2010 3;31(3):454-458;
crossref pmid pmc
18. Hwang G, Oh CW, Bang JS, Jung CK, Kwon OK, Kim JE, et al. Superficial temporal artery to middle cerebral artery bypass in acute ischemic stroke and stroke in progress. Neurosurgery. 2011 3;68(3):723-729; discussion 729-30
crossref pmid pdf
19. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 3;44(3):870-947;
crossref pmid
20. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med. 2015 6;372(24):2296-2306;
crossref pmid
21. Kang DH, Hwang YH, Kim YS, Park J, Kwon O, Jung C. Direct thrombus retrieval using the reperfusion catheter of the penumbra system: forced-suction thrombectomy in acute ischemic stroke. AJNR Am J Neuroradiol. 2011 2;32(2):283-287;
crossref pmid pmc
22. Kass-Hout T, Amuluru K, Al-Derazi Y, Singh P, Prestigiacomo CJ, Gandhi CD. Endovascular therapy for acute ischemic stroke: time to enter a new era in stroke management. World Neurosurg. 2015 6;83(6):951-953;
crossref pmid
23. Kim D, Ford GA, Kidwell CS, Starkman S, Vinuela F, Duckwiler GR, et al. Intra-arterial thrombolysis for acute stroke in patients 80 and older: a comparison of results in patients younger than 80 years. AJNR Am J Neuroradiol. 2007 1;28(1):159-163;
pmid pmc
24. Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I, et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology. 2004 1;62(1):77-81;
crossref pmid
25. Mazighi M, Labreuche J, Meseguer E, Serfaty JM, Laissy JP, Lavallee PC, et al. Impact of a combined intra-venous/intra-arterial approach in octogenarians. Cerebrovasc Dis. 2011 6;31(6):559-565;
crossref pmid
26. Mono ML, Romagna L, Jung S, Arnold M, Galimanis A, Fischer U, et al. Intra-arterial thrombolysis for acute ischemic stroke in octogenarians. Cerebrovasc Dis. 2012 2;33(2):116-122;
crossref pmid
27. O'Donnell MJ, Kapral MK, Fang J, Saposnik G, Eikelboom JW, Oczkowski W, et al. Gastrointestinal bleeding after acute ischemic stroke. Neurology. 2008 8;71(9):650-655;
crossref pmid
28. Park H, Hwang GJ, Jin SC, Jung CK, Bang JS, Han MK, et al. A retrieval thrombectomy technique with the Solitaire stent in a large cerebral artery occlusion. Acta Neurochir (Wien). 2011 8;153(8):1625-1631;
crossref pmid pdf
29. Poisson SN, Johnston SC, Josephson SA. Urinary tract infections complicating stroke: mechanisms, consequences, and possible solutions. Stroke. 2010 4;41(4):e180-e184;
crossref pmid
30. Qureshi AI, Suri MF, Georgiadis AL, Vazquez G, Janjua NA. Intra-arterial recanalization techniques for patients 80 years or older with acute ischemic stroke: pooled analysis from 4 prospective studies. AJNR Am J Neuroradiol. 2009 6;30(6):1184-1189;
crossref pmid pmc
31. Rocco A, Pasquini M, Cecconi E, Sirimarco G, Ricciardi MC, Vicenzini E, et al. Monitoring after the acute stage of stroke: a prospective study. Stroke. 2007 4;38(4):1225-1228;
crossref pmid
32. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. N Engl J Med. 2015 6;372(24):2285-2295;
crossref pmid
33. Stott DJ, Falconer A, Miller H, Tilston JC, Langhorne P. Urinary tract infection after stroke. QJM. 2009 4;102(4):243-249;
crossref pmid pdf
34. Vargas M, Horcajada JP, Obach V, Revilla M, Cervera A, Torres F, et al. Clinical consequences of infection in patients with acute stroke: is it prime time for further antibiotic trials? Stroke. 2006 2;37(2):461-465;
crossref pmid
35. Walter U, Knoblich R, Steinhagen V, Donat M, Benecke R, Kloth A. Predictors of pneumonia in acute stroke patients admitted to a neurological intensive care unit. J Neurol. 2007 10;254(10):1323-1329;
crossref pmid pdf
36. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011 9;11(9):110
crossref pmid pmc pdf
Fig. 1

Distributions of modified Rankin scale score at 3 (A) and 12 months (B) after stroke Note. EVT = endovascular treatment.

Table 1

Basic demographic and clinical data for the EVT and non-EVT groups

EVT = endovascular treatment; mRS = modified Rankin scale; NIHSS = National Institute of Health Stroke Scale; SD = standard deviation; TOAST = Trial of Org 10172 Acute Stroke Treatment; tPA = tissue plasminogen activator

EVT (n = 56, 35.9%) Non-EVT (n = 100, 64.1%) p value
Female 32 (57.1%) 64 (64.0%) 0.493
Age (SD), years 84.1 (3.38) 85.0 (4.50) 0.159
Past history
 Smoking 10 (17.9%) 23 (23.0%) 0.542
 Stroke 16 (28.6%) 32 (32.0%) 0.720
 Hypertension 35 (62.5%) 63 (63.0%) 1.000
 Diabetes mellitus 13 (23.2%) 18 (18.0%) 0.531
 Hyperlipidemia 3 (5.4%) 8 (8.0%) 0.747
 Atrial fibrillation 23 (41.1%) 26 (26.0%) 0.072
 Coronary heart disease 10 (17.9%) 8 (8.0%) 0.073
Prestroke mRS score 0.423
 0 45 (80.4%) 72 (72.0%)
 1 5 (8.9%) 16 (16.0%)
 2 6 (10.7%) 12 (12.0%)
Occlusion site 0.478
 Internal carotid 10 (17.8%) 24 (24.0%)
 Middle cerebral 37 (66.1%) 67 (67.0%)
 Basilar 7 (12.5%) 6 (6.0%)
 Vertebral 2 (3.6%) 3 (3.0%)
TOAST classification 0.146
 Large artery atherosclerosis 12 (21.4%) 34 (34.0%)
 Cardioembolism 38 (67.9%) 50 (50%)
 Small artery occlusion - -
 Other cause 0 (0%) 2 (2.0%)
 Undetermined cause 6 (10.7%) 14 (14.0%)
Time from onset 0.606
 < 3 hours 37 (66.1%) 61 (61.0%)
 3-8 hours 19 (33.9%) 39 (39.0%)
Initial NIHSS score (SD) 14.2 (7.57) 14.6 (7.84) 0.763
Intravenous tPA use 35 (62.5%) 60 (60.0%) 0.864
Table 2

Functional outcomes, in-hospital morbidities, symptomatic hemorrhages, and in-hospital mortalities in the EVT and non-EVT groups

EVT = endovascular treatment; mRS = modified Rankin Scale.

*Symptomatic hemorrhage was defined as a hemorrhage associated with a ≥ 4-point increase in the NIHSS score or a 1-point deterioration in level of consciousness.

Each comparison of the two study groups was adjusted for age, time from onset, initial NIHSS score, and prestroke mRS score

(n = 56)
(n = 100)
Unadjusted odds ratio
(95% confidence interval)
Adjusted odds ratio
(95% confidence interval)
p value
Good functional outcome (mRS 0-2)
 3 months 20 (35.7%) 11 (11.0%) 4.495 (1.957-10.322) 4.779 (1.972-11.579) 0.001
 12 months 20 (35.7%) 14 (14.0%) 3.413 (1.555-7.490) 3.705 (1.574-8.722) 0.003
In-hospital morbidities
 Endotracheal intubation 10 (17.9%) 17 (17.0%) 1.061 (0.449-2.509) 1.062 (0.415-2.714) 0.901
 Gastrointestinal bleeding 1 (1.8%) 8 (8.0%) 0.209 (0.025-1.717) 0.185 (0.022-1.585) 0.124
 Pneumonia 7 (12.5%) 29 (29.0%) 0.350 (0.142-0.862) 0.262 (0.098-0.703) 0.008
 Urinary tract infection 9 (16.1%) 34 (34.0%) 0.372 (0.163-0.848) 0.256 (0.099-0.657) 0.005
Symptomatic hemorrhage* 6 (10.7%) 2 (2.0%) 5.880 (1.145-30.196) 6.859 (1.139-41.317) 0.036
In-hospital mortality 7 (12.5%) 8 (8.0%) 1.643 (0.562-4.799) 1.380 (0.408-4.664) 0.604

Editorial Office
The Journal of Cerebrovascular and Endovascular Neurosurgery (JCEN), Department of Neurosurgery, Wonkwang University
School of Medicine and Hospital, 895, Muwang-ro, Iksan-si, Jeollabuk-do 54538, Korea
Tel: +82-2-2279-9560    Fax: +82-2-2279-9561    E-mail: editor.jcen@the-jcen.org                

Copyright © 2023 by Korean Society of Cerebrovascular Surgeons and Korean NeuroEndovascular Society.

Developed in M2PI

Close layer
prev next